- In July 2026, Alnylam Pharmaceuticals reported past progress on its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference, including initiating the Phase 2 APPlauDS trial of mivelsiran in Down syndrome-associated Alzheimer’s disease, completing enrollment in the Phase 2 cAPPricorn-1 study in cerebral amyloid angiopathy, and advancing ALN-5288 into a first-in-human trial with Regeneron.
- Early mivelsiran data in Alzheimer’s disease showed sustained biomarker reductions and a reassuring safety profile, underscoring Alnylam’s push to extend its RNAi platform beyond rare diseases into complex CNS conditions.
- We’ll now examine how this Alzheimer’s-focused pipeline progress, especially the mivelsiran Phase 2 expansion, interacts with Alnylam’s existing investment narrative.
We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Alnylam Pharmaceuticals Investment Narrative Recap
To own Alnylam today, you have to believe its RNAi platform can keep supporting the TTR franchise while gradually broadening into larger indications without overwhelming margins. The new Alzheimer’s data and mivelsiran Phase 2 expansion look directionally positive for diversification, but they do not change that the key near term catalyst and main risk still sit in execution and pricing for the TTR portfolio, particularly AMVUTTRA.
The Alzheimer’s Association conference update on mivelsiran is the clearest link to Alnylam’s longer term diversification story, showing how management is pushing RNAi into high-prevalence CNS diseases. This sits alongside earlier 2026 news, such as Alnylam’s Inceptive Nucleics AI collaboration, which aims to sharpen target discovery. Together, they frame how the company is investing heavily in R&D that could either support future upside or prolong margin pressure if programs disappoint.
Yet beneath this progress, investors should also be aware that...
Read the full narrative on Alnylam Pharmaceuticals (it's free!)
Alnylam Pharmaceuticals' narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029. This requires 28.3% yearly revenue growth and about a $1.5 billion earnings increase from $538.0 million today.
Uncover how Alnylam Pharmaceuticals' forecasts yield a $434.72 fair value, a 56% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming Alnylam could reach about US$11.9 billion in revenue and US$3.6 billion in earnings by 2029, which is a far more upbeat view than consensus and depends heavily on Alzheimer’s and other non rare disease programs succeeding rather than stalling under high R&D costs.
Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth just $320.21!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com